Ft. Lauderdale, FL, Feb. 02, 2018 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of patient-centric, clinical data management technology, has completed the acquisition of certain assets and assumed certain liabilities of Algorics, a provider of clinical analytics solutions and software.  

This acquisition significantly enhances OmniComm’s product portfolio with advanced data analytics capabilities, specialized algorithms and artificial intelligence/machine learning, developed by Algorics. Acuity is a system-agnostic platform that provides powerful and flexible data aggregation, and visualization that drive actionable knowledge in real time. Acuity improves productivity and minimizes risk in clinical research by providing a clear vision of clinical and operational data.  

Acuity will provide enhanced real-time and cross-study reporting capabilities for OmniComm’s TrialMaster® and TrialOne® electronic data capture (EDC) product lines.

“This is definitely a very good acquisition for both OmniComm and Algorics,” said Nithiya Ananthakrishnan, who was the CEO and founder of Algorics. “By joining with OmniComm, we will accelerate our goal of becoming the best-in-class solution for risk-based monitoring and clinical data analytics. We look forward to bringing additional competitive advantages to OmniComm’s customers by delivering end-to-end RBM solutions and specialized data analytics expertise.”

Mr. Ananthakrishnan will assume the role of senior vice president of Data Sciences at OmniComm, reporting to Stephen Johnson, president and CEO of OmniComm.

“Adding this RBM and analytics platform to our existing product lines fills a strong need for our clients,” Mr. Johnson said. “Due to a common technology stack, the Acuity platform perfectly integrates with our TrialMaster and TrialOne solutions. We are excited to share our newest technology with our clients to help them derive more power from their clinical research data.”

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations (CROs), diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Please visit www.omnicomm.com for more information.

Investor Relations 
OmniComm Systems, Inc.
+1.954.473.1254
INVREL@omnicomm.com